{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:50:17Z","timestamp":1754164217110,"version":"3.41.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Eyelid basal cell carcinoma (BCC) is usually cured by surgery. However, for a minority of patients, extensive disease progression and recurrence contraindicate surgery or radiotherapy because of severe ocular morbidity. The hedgehog signaling pathway inhibitor vismodegib is becoming the key treatment for this specific form.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>The aim of this review was to define the role of surgery after vismodegib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>A literature search of the PubMed, Cochrane Library, ScienceDirect, and Embase databases was conducted for all articles published up to March 2021 to identify studies that examined treatment of BCC of the eyelid by vismodegib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Level 1 evidence was found for the use of vismodegib as neoadjuvant therapy in locally advanced eyelid BCC contraindicated to surgery and\/or radiotherapy with a rather good tolerance of treatment. Level 3 evidence was found for the role of surgical excision of residual clinically suspicious lesions as for the indication of eyelid reconstruction after mapping or during residual tumoral resection if frozen sections or Mohs surgery were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Vismodegib is a well-tolerated treatment for advanced periorbital BCC. The hedgehog signaling pathway inhibitor vismodegib is a potential treatment option in patients with these challenging tumors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003508","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T14:00:09Z","timestamp":1662127209000},"page":"905-911","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review"],"prefix":"10.1097","volume":"48","author":[{"given":"Delphine","family":"Peillex","sequence":"first","affiliation":[{"name":"Oral and Maxillofacial Surgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Passemard","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Magnin","sequence":"additional","affiliation":[{"name":"Radiology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Rouanet","sequence":"additional","affiliation":[{"name":"Dermatology,University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Clermont-Ferrand, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Pham Dang","sequence":"additional","affiliation":[{"name":"Oral and Maxillofacial Surgery,"},{"name":"UMR Inserm\/UdA, U1107, Neuro-Dol, Trigeminal Pain and Migraine, Universit\u00e9 d'Auvergne, Clermont-Ferrand, France;"},{"name":"EnCoV, IP, UMR 6602 CNRS, Clermont-Ferrand University Hospital Estaing, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"101046","DOI":"10.1016\/j.disamonth.2020.101046","article-title":"Periocular skin cancer: diagnosis and management","volume":"66","author":"Moran","year":"2020","journal-title":"Dis Mon"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ophtha.2003.11.004","article-title":"The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up","volume":"111","author":"Malhotra","year":"2004","journal-title":"Ophthalmology"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/107327481602300207","article-title":"Role of vismodegib in the management of advanced periocular basal cell carcinoma","volume":"23","author":"Cox","year":"2016","journal-title":"Cancer Control"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade","volume":"5","author":"Lipson","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/dsu.12424","article-title":"Application of intense pulsed light in the treatment of dermatologic disease: a systematic review","volume":"40","author":"Wat","year":"2014","journal-title":"Dermatol Surg"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","article-title":"Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma","volume":"29","author":"Yin","year":"2013","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/DSS.0000000000001640","article-title":"Oral hedgehog pathway inhibition as a means for ocular salvage in locally advanced intraorbital basal cell carcinoma","volume":"45","author":"Mathis","year":"2019","journal-title":"Dermatol Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","article-title":"Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial","volume":"138","author":"Ben Ishai","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.1097\/GOX.0000000000001424","article-title":"Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases","volume":"5","author":"Wong","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IOP.0000000000001251","article-title":"Impact of food and drug administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bjophthalmol-2018-312277","article-title":"Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma","volume":"103","author":"Sagiv","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/IOP.0000000000000388","article-title":"Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area","volume":"31","author":"Demirci","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","article-title":"Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma","volume":"207","author":"Eiger-Moscovich","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jaad.2015.12.035","article-title":"Four-year experience with vismodegib hedgehog inhibitor therapy","volume":"74","author":"Simone","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","article-title":"An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma","volume":"71","author":"Ally","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","article-title":"Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome","volume":"160","author":"Ozgur","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jamaophthalmol.2013.5018","article-title":"Vismodegib for periocular and orbital basal cell carcinoma","volume":"131","author":"Gill","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.anplas.2015.01.002","article-title":"Carcinomes basocellulaires localement avanc\u00e9s : int\u00e9r\u00eat de traitements combin\u00e9s, alternatifs \u00e0 la chirurgie","volume":"60","author":"Amici","year":"2015","journal-title":"Ann Chir Plast Esthet"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/jamadermatol.2015.4592","article-title":"Effective and tolerable treatment of advanced basal cell carcinoma with vismodegib despite renal insufficiency","volume":"152","author":"Maul","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/jamadermatol.2015.0326","article-title":"Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma","volume":"151","author":"Pollom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/DSS.0000000000000731","article-title":"Histologic findings of tumor lysis in advanced basal cell carcinoma treated with vismodegib","volume":"42","author":"Powell","year":"2016","journal-title":"Dermatol Surg"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamadermatol.2013.1798","article-title":"New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases","volume":"149","author":"Aasi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"R24-20250731","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.ijom.2020.03.006","article-title":"Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib","volume":"49","author":"Glen","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"R25-20250731","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaophthalmol.2013.4430","article-title":"Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma","volume":"131","author":"Kahana","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R26-20250731","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ad.2018.05.022","article-title":"Aggressive inferior eyelid basal cell carcinoma: advantage of neoadjuvant vismodegib","volume":"110","author":"Monteiro","year":"2019","journal-title":"Actas Dermosifiliogr"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1080\/0284186X.2016.1206212","article-title":"Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma","volume":"55","author":"Paulsen","year":"2016","journal-title":"Acta Oncol"},{"key":"R29-20250731","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaad.2019.12.002","article-title":"Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial","volume":"82","author":"Fosko","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R30-20250731","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-S\u00e9guin","year":"2017","journal-title":"Eur J Cancer"},{"key":"R31-20250731","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1524-475X.2008.00430.x","article-title":"Hedgehog signaling is essential for normal wound healing","volume":"16","author":"Le","year":"2008","journal-title":"Wound Repair Regen"},{"key":"R32-20250731","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2146\/ajhp120311","article-title":"Vismodegib for the treatment of basal cell skin cancer","volume":"70","author":"Poggi","year":"2013","journal-title":"Am J Health Syst Pharm"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:07:21Z","timestamp":1753999641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003508","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2022,8,3]]}}}